.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AH03_Peramivir.Peramivir

Information

Peramivir is a neuraminidase inhibitor antiviral drug used for the treatment of influenza. It is administered primarily as a single-dose intravenous infusion for adults with acute uncomplicated influenza. Peramivir is approved for use in the United States and several other countries.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects after a single 600 mg intravenous dose.

References

1. Matsuo, Y, et al., & Wajima, T (2015). Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. Antimicrobial agents and chemotherapy 59(11) 6755–6762. DOI:10.1128/AAC.00799-15 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26282420

2. Zhang, D, et al., & Liu, H (2015). Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects. Xenobiotica; the fate of foreign compounds in biological systems 45(3) 239–243. DOI:10.3109/00498254.2014.960907 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25231091

3. Sugaya, N, et al., & Takahashi, T (2012). Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrobial agents and chemotherapy 56(1) 369–377. DOI:10.1128/AAC.00132-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22024821

Revisions

• 06/2025 initial generated model